(Q30414395)

English

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1 reference

based on heuristic

inferred from title

Seth M Steinberg

7

object named as

Seth M Steinberg

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

author name string

Osama E Rahma

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

J Michael Hamilton

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Malgorzata Wojtowicz

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Omar Dakheel

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Sarah Bernstein

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

David J Liewehr

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Samir N Khleif

8

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

publication date

24 February 2014

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Journal of Translational Medicine

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

55

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Ras in cancer and developmental diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Mutations of ras genes in human tumors (review).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Interleukin 2 in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

ras oncogenes in human cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

MHC class II-restricted presentation of intracellular antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

20 June 2018

RAS oncogenes: the first 30 years.

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-12-55

21 January 2018

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-12-55

21 January 2018

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-12-55

21 January 2018

Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant.

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-12-55

21 January 2018

Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

26 November 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3942063

26 November 2018

Identification of self peptides bound to purified HLA-B27

1 reference

https://api.crossref.org/works/10.1186%2F1479-5876-12-55

21 January 2018

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24565030

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/24565030

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24565030

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/24565030

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

1 reference

https://pubmed.ncbi.nlm.nih.gov/24565030

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1479-5876-12-55

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30414395&oldid=2194832910"